Please assess the completion status of the following clinical trial:

Trial Title: An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. diagnosis of essential hypertension~2. failure to respond adequately to six weeks treatment with amlodipine 5 mg monotherapy~3. provision of written informed consent~Exclusion criteria:~1. clinical conditions which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine for the planned duration of this trial (e.g. populations where labeling of either product recommends against its utilization)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Telmisartan80mg+Amlodipine5mg (Type: EXPERIMENTAL): combination therapy
- amlodipine 5 mg (Type: ACTIVE_COMPARATOR): Monotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).